INSR and Parkinson disease: Key GO terms aligned with disease mechanisms (e.g. “insulin receptor binding” for diabetes and “ubiquitin-dependent catabolism” for Parkinson’s) highlighting DA-HGL’s ability to uncover functional landscapes and therapeutic targets.